UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 6, 2007
IMCLONE SYSTEMS INCORPORATED
(Exact name of registrant as specified in its charter)
Delaware (State or other jurisdiction of Incorporation) | 0-19612 (Commission File Number) | 04-2834797 (IRS Employer Identification No.) |
180 Varick Street
New York, New York 10014
(Address of principal executive offices) (Zip Code)
(212) 645-1405
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.02. Termination of a Material Definitive Agreement.
ImClone Systems Incorporated (“ImClone Systems”) announced today that it has opted-out of its development agreement with UCB S.A. (“UCB”) for CDP-791. CDP-791 is UCB’s proprietary antibody product candidate targeting the vascular endothelial growth factor receptor-2 (“VEGFr-2”) pathway. ImClone Systems opted-out of this agreement in order to focus its resources on the development of IMC-1121B, ImClone Systems’ proprietary antibody product candidate targeting VEGFr-2.
A copy of the press release is attached as exhibit 99.1 to this report.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
Exhibit No. | | Description |
| | |
99.1 | | Press Release of ImClone Systems Incorporated dated February 6, 2007. |
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| IMCLONE SYSTEMS INCORPORATED |
| (Registrant) |
| |
| |
Dated: February 6, 2007 | By: | /s/ Daniel J. O’Connor |
| | Daniel J. O’Connor |
| | Vice President, Interim General Counsel |
3
